WHG
RXRX icon

Westwood Holdings Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Westwood Holdings Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-66,872
Closed -$446K – 519
2023
Q1 		$446K Buy
+66,872
New +$531K ﹤0.01% 415

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Westwood Holdings Group's RXRX Position: Q2 2023 in Review

Westwood Holdings Group sold out of Recursion Pharmaceuticals (RXRX) in Q2 2023, closing a stake of 66,872 shares — an estimated $446K sold.

Westwood Holdings Group first reported a position in RXRX in Q1 2023 and held it in 1 quarter. The position peaked at $446K in Q1 2023. 158 funds tracked by Wall St. Rank hold RXRX as of Q2 2023.

  • Westwood Holdings Group reported no remaining Recursion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Westwood Holdings Group sold 66,872 Recursion Pharmaceuticals shares in Q2 2023, an estimated $446K.
  • Westwood Holdings Group first reported a position in Recursion Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Westwood Holdings Group's Recursion Pharmaceuticals position peaked at $446K in Q1 2023.
  • 158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2023.

Based on Westwood Holdings Group's 13F filing for Q2 2023, filed 11 Aug 2023.